Zanolimumab

Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.^[1] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,^[2] cutaneous and peripheral T-cell lymphoma.^[3]^[4] Development of the drug was ultimately discontinued with termination of all trials.^[5]

References

^ Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C (December 2008). "Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome". Expert Opinion on Biological Therapy. 8 (12): 1929–39. doi:10.1517/14712590802528696. PMID 18990079. S2CID 58115371.
^ "TenX BioPharma". Archived from the original on April 11, 2010. Retrieved August 20, 2010.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab Archived 2011-06-04 at the Wayback Machine, American Medical Association.
^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
^ "Status of clinical trials for Zanolimumab". Archived from the original on 27 May 2013. Retrieved 6 November 2011.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.